Concurrent EGFR and KRAS mutations in non-small cell lung cancer: Challenging the paradigm of linear targeted therapy

Mohsen  Farrokhpour; Seyedeh Hatameh  Asadinejad Tahergourabi; Niloofar  Keikhaei; Hamed  Hekmat Nejad

doi:10.61882/jcbior.6.2.299

Authors

Mohsen Farrokhpour 1. Firouzgar Hospital, Department of Internal Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Seyedeh Hatameh Asadinejad Tahergourabi 1. Firouzgar Hospital, Department of Internal Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Niloofar Keikhaei 2. Sayad Shirazi Hospital, Department of Internal Medicine, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
Hamed Hekmat Nejad Department of Basic Sciences, Sari Agricultural Sciences and Natural Resources University, Sari, Iran https://orcid.org/0000-0002-5716-9240

DOI:

https://doi.org/10.61882/jcbior.6.2.299

Keywords:

Non-small lung cancer, KRAS, EGFR, Mutation, Targeted therapy

Abstract

No abstract.

References

1. Tan AC, Tan DSW. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J Clin Oncol. 2022;40(6):611-625. DOI: 10.1200/JCO.21.01626

PMID: 34985916

2. Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017;17(11):637-658. DOI: 10.1038/nrc.2017.84 PMID: 29068003

3. Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021;384(25):2371-2381.

DOI: 10.1056/NEJMoa2103695 PMID: 34096690

4. Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. N Engl J Med. 2022;387(2):120-131. DOI: 10.1056/NEJMoa2204619 PMID: 35658005

5. Takamochi K, Oh S, Suzuki K. Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers. Oncol Lett. 2013;6(5):1207-1212.

DOI: 10.3892/ol.2013.1551 PMID: 24179496

6. Ma JW, Fu YL, Miao L, Li M. Imaging of synchronous multiple primary lung adenocarcinoma with concomitant EGFR and KRAS mutations: a case report and review of the literature. Transl Cancer Res. 2021;10(5):2509-2515. DOI: 10.21037/tcr-20-3258 PMID: 35116566

7. Ernst SM, Uzun S, Paats MS, van Marion R, Atmodimedjo PN, de Jonge E, et al. Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases. JCO Precis Oncol. 2023;7:e2300451. DOI: 10.1200/PO.23.00451 PMID: 38096473

8. Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022;15(1):173.

DOI: 10.1186/s13045-022-01391-4 PMID: 36482474

9. Laface C, Maselli FM, Santoro AN, Iaia ML, Ambrogio F, Laterza M, et al. The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies. Pharmaceutics. 2023;15(6):1604. DOI: 10.3390/pharmaceutics15061604

PMID: 37376053

10. Ou X, Gao G, Habaz IA, Wang Y. Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies. MedComm (2020). 2024;5(9):e694.

DOI: 10.1002/mco2.694 PMID: 39184861